BBL
CKPT

Beck Bode LLC’s Checkpoint Therapeutics CKPT Stock Holding History

Beck Bode LLC’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$18K – 69
2018
Q4 		$18K Buy
+1,000
New +$23.8K 0.01% 69

Other funds holding CKPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FAM
Fenimore Asset Management Cobleskill, New York $4.83B AUM 9.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

Beck Bode LLC's CKPT Position: Q1 2019 in Review

Beck Bode LLC sold out of Checkpoint Therapeutics (CKPT) in Q1 2019, closing a stake of 1,000 shares — an estimated $18K sold.

Beck Bode LLC first reported a position in CKPT in Q4 2018 and held it in 1 quarter. The position peaked at $18K in Q4 2018. 22 funds tracked by Wall St. Rank hold CKPT as of Q1 2019.

  • Beck Bode LLC reported no remaining Checkpoint Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Beck Bode LLC sold 1,000 Checkpoint Therapeutics shares in Q1 2019, an estimated $18K.
  • Beck Bode LLC first reported a position in Checkpoint Therapeutics in Q4 2018 and held it in 1 quarter.
  • Beck Bode LLC's Checkpoint Therapeutics position peaked at $18K in Q4 2018.
  • 22 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2019.

Based on Beck Bode LLC's 13F filing for Q1 2019, filed 27 Nov 2019.